Biomarkers and surrogate endpoints

被引：162

作者：

Aronson, JK ^{[1
]}

机构：

[1] Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2005年 / 59卷 / 05期

关键词：

D O I：

10.1111/j.1365-2125.2005.02435.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：491 / 494

页数：4

共 22 条

[1] Khat chewing is a risk factor for acute myocardial infarction: a case-control study [J].

Al-Motarreb, A ;

Briancon, S ;

Al-Jaber, N ;

Al-Adhi, B ;

Al-Jailani, F ;

Salek, MS ;

Broadley, KJ .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (05) :574-581

[2]

[Anonymous], 1989, NEW ENGL J MED, V321, P406

[3]

BOONE CW, 1993, J CELL BIOCHEM, P37

[4] GAMMA-GLUTAMYLTRANSFERASE AS A POTENTIAL SURROGATE MARKER FOR DETECTION OF THE NON-A, NON-B CARRIER STATE [J].

BROTMAN, B ;

PRINCE, AM .

VOX SANGUINIS, 1988, 54 (03) :144-147

[5]

Cohen A, 2004, BRIT J CLIN PHARMACO, V58, pS742

[6]

COHN JN, 1991, HERZ, V16, P267

[7] Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients [J].

Davies, J ;

Gavin, A ;

Band, M ;

Morris, A ;

Struthers, A .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (05) :520-523

[8] Multiple-dose activated charcoal for treatment of yellow oleander poisoning: a single-blind, randomised, placebo-controlled trial [J].

de Silva, HA ;

Fonseka, MMD ;

Pathmeswaran, A ;

Alahakone, DGS ;

Ratnatilake, GA ;

Gunatilake, SB ;

Ranasinha, CD ;

Lalloo, DG ;

Aronson, JK ;

de Silva, HJ .

LANCET, 2003, 361 (9373) :1935-1938

[9]

Downing GJ, 2000, Biomarkers and surrogate endpoints, P1

[10] Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects [J].

Dumont, GJH ;

de Visser, SJ ;

Cohen, AF ;

van Gerven, JMA .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (05) :495-510

← 1 2 3 →